First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam
Clinical Scorecard: Real-World Outcomes of First-Line CDK4/6 Inhibitor Therapy in HR-Positive, HER2-Negative Metastatic Breast Cancer: Insights from Ho Chi Minh City Oncology Hospital, Vietnam
At a Glance
Category
Detail
Condition
HR-positive, HER2-negative metastatic breast cancer
Key Mechanisms
Endocrine therapy combined with CDK4/6 inhibition (ribociclib or palbociclib) improves outcomes.
Target Population
Women with HR-positive, HER2-negative recurrent or metastatic breast cancer.
Care Setting
Oncology hospital setting in Vietnam.
Key Highlights
Median progression-free survival (PFS) was 28.0 months.
Overall survival (OS) rates at 12 and 24 months were 88.8% and 87.8%, respectively.
58.8% of patients experienced grade 3–4 neutropenia, managed with dose adjustments.
Guideline-Based Recommendations
Diagnosis
HR-positive, HER2-negative metastatic breast cancer diagnosis confirmed.
Management
First-line treatment with CDK4/6 inhibitors combined with endocrine therapy is recommended.
Monitoring & Follow-up
Monitor for treatment-related toxicities, particularly neutropenia.
Risks
Potential for grade 3–4 neutropenia and endocrine resistance.
Patient & Prescribing Data
107 women treated at Ho Chi Minh City Oncology Hospital.
First-line therapy included ribociclib or palbociclib with an aromatase inhibitor or fulvestrant.
Clinical Best Practices
Consider dose interruption or reduction for managing neutropenia.
Utilize CDK4/6 inhibitors in combination with endocrine therapy for improved outcomes.
